Skip to main content
OpenTrials
Recruiting

NCT Number: NCT06465160

A Study to Evaluate the MNV-201 in Patients With Low Risk MDS

Myelodysplastic syndromes (MDS) are a group of bone marrow failures that occur when the blood-forming cells in the bone marrow become abnormal leading to an abnormal differentiation and production of one or more blood cell types. According to the American Cancer Society, in the United States, MDS occurs at a rate of 4.8 cases for every 100,000 people; MDS affects an estimated 60,000 persons in the United States, with 10,000-15,000 new cases recorded each year. MDS is defined by ineffective haematopoiesis resulting in blood cytopenias (a reduction in the number of mature blood cells), and clonal instability with a risk of evolution to acute myeloid leukaemia (AML). Patients with MDS collectively have a high symptom burden and are also at risk of death from complications of cytopenias and AML. MDS is generally a disease that develops with ageing; the median age at diagnosis of MDS is ~70 years, and patients frequently have comorbid conditions. The goals of therapy for patients with MDS are to reduce disease-associated symptoms and the risk of disease progression and death, thereby improving both quality and quantity of life.

Minovia Therapeutics Ltd. ("Minovia") is a biotech company developing novel therapeutics based on its mitochondrial augmentation technology (MAT). MNV-201 is a cell therapy produced by MAT that consists of the participant's autologous CD34+ hematopoietic stem and progenitor cells (HSPCs) enriched with allogeneic placental-derived mitochondria, manufactured in Minovia's GMP facility.

Recruiting

Interested in participating?

Request Info

Key information

Conditions

Myelodysplastic Syndromes Anemia Bone Marrow Diseases Hematologic Diseases Hemic and Lymphatic Diseases

Age range

18 year–100 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 1

Primary location

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Male or female participants aged from 18 years old and above.
  • Low Risk MDS diagnosis with R-IPSS score of ≤3 with mutational burden and/or low burden of high-risk mutations as defined by IPSS-M.
  • Participant has anemia and is blood transfusion dependent (received 2 or more units of packed blood per /4 weeks for at least 8 weeks before enrollment).
  • A baseline natural history of the participant is available, including anemia and transfusions frequency at least 6 months before enrollment.
  • Participant has utilized all existing treatments for low risk MDS that are approved and available to him or is not medically eligible for those treatment options.
  • Participant is not eligible for Allogeneic Bone Marrow Transplantation.
  • Participant is medically able to undergo the study interventions, as determined by the investigator.
  • Participant and/or legal guardian(s) able to understand and provide voluntary written informed consent.

Exclusion criteria

  • History of infection with HIV-1, HIV-2, or HTLV I/II.
  • Current active infection with HBV , HCV, HTLV I/II, Treponema Pallidum or HIV I-II.
  • Participant is unable to undergo apheresis.
  • Participant has known hypersensitivity to murine proteins or iron-dextran.
  • Participant has chronic severe infection.
  • Participant has disease or condition that may risk the participant or interfere with the ability to interpret the study results.
  • History of treatment for malignant disease (other than excision of non-melanoma skin cancer) in the last 2 years
  • Pregnancy or breastfeeding
  • History of treatment with gene therapy, bone marrow or allogeneic cord blood transplantation.
  • Currently participating in another clinical trial, or participation in another clinical trial within 1 year prior to study enrollment.
  • In the opinion of the Investigator, the participant is unsuitable for participating in the study for any reason.

Treatment and study plan

MNV-201 (Autologous CD34+ Cells Enriched with allogenic Placenta Derived Mitochondria)

Biological

The participant will undergo 5 days of mobilization by G-CSF administration (Neupogen) once a day during 5 days.

On the 5th day, and after receiving the last dose of Neupogen, the participant will undergo Apheresis to collect CD34+ cells.

MNV-201 consists of autologous CD34+ cells enriched with allogeneic placenta derived mitochondria. Autologous CD34+ cells are isolated from the participant's peripheral blood after mobilization by apheresis. Allogeneic mitochondria are isolated under aseptic conditions from healthy donor placenta, cryopreserved and qualified before use.

Each product package will consist of a ready-for-injection sterile infusion bag containing clinical grade MNV-201 product for IV infusion for a single specified (autologous) participant.

Primary outcomes

  1. Occurrence of treatment-related adverse events

    Time frame: 1 year

    Occurrence of treatment-related adverse events as assessed by CTCAE v5.0 following MNV-201 infusion, during a follow up period of 12 months following first dosing (Part 1) and 6 months following second dosing (Part 2), where relevant.

Secondary outcomes

  1. Anemia assessment

    Time frame: 1 year

    Hemoglobin rise measured by CBC of at least 1 g/dL from baseline during a follow up period of 6- and 12-months post treatment (Part 1) or 6 months post

  2. Blood transfusion assessment

    Time frame: 1 year

    Reduction in frequency of blood transfusions during a follow up period of 6- and 12-months post treatment (Part 1) or 6 months post treatment (Part 2) compared to the 6 months period before treatment.

  3. Assessment of Quality of Life by the Functional Assessment of Cancer Therapy - Anemia

    Time frame: 1 year

    Change in health-related quality-of-life (HRQoL) assessed by the Functional Assessment of Cancer Therapy - Anemia (FACT-An) from baseline during a follow up period of 6- and 12-months post treatment (Part 1) or 6 months post treatment (Part 2).

Study contacts

Contact information is provided by the study sponsor or research team.

Lea Bensoussan, MSc

CONTACT

[email protected]

0586101291 ext. 972

Sponsors and collaborators

Lead sponsor

Minovia Therapeutics Ltd.

Industry

Registry information

Official study title

A Phase Ib, Open Label, Single or Repeated Dose Exploration Clinical Study to Evaluate the Safety and Therapeutic Effects of Infusion of MNV-201 (Autologous CD34+ Cells Enriched With Allogenic Placenta Derived Mitochondria) in Patients With Low-Risk Myelodysplastic Syndrome

Important dates

Study start
2024
Primary completion
2026
Study completion
2029
First posted
Jun 18, 2024
Registry last updated
Oct 1, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.